- Home
- GBX vs HRMY Comparison
GBX vs HRMY Comparison
Compare GBX & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBX
- HRMY
- Stock Information
- Founded
- GBX 1974
- HRMY 2017
- Country
- GBX United States
- HRMY United States
- Employees
- GBX N/A
- HRMY N/A
- Industry
- GBX Railroads
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- GBX Industrials
- HRMY Health Care
- Exchange
- GBX Nasdaq
- HRMY Nasdaq
- Market Cap
- GBX 1.8B
- HRMY 1.6B
- IPO Year
- GBX N/A
- HRMY 2020
- Fundamental
- Price
- GBX $44.36
- HRMY $34.05
- Analyst Decision
- GBX Hold
- HRMY Strong Buy
- Analyst Count
- GBX 2
- HRMY 8
- Target Price
- GBX $57.00
- HRMY $52.88
- AVG Volume (30 Days)
- GBX 464.3K
- HRMY 701.6K
- Earning Date
- GBX 07-07-2025
- HRMY 05-06-2025
- Dividend Yield
- GBX 2.86%
- HRMY N/A
- EPS Growth
- GBX 85.75
- HRMY 13.13
- EPS
- GBX 6.26
- HRMY 2.62
- Revenue
- GBX $3,511,200,000.00
- HRMY $744,852,000.00
- Revenue This Year
- GBX N/A
- HRMY $20.06
- Revenue Next Year
- GBX N/A
- HRMY $18.40
- P/E Ratio
- GBX $7.14
- HRMY $13.10
- Revenue Growth
- GBX N/A
- HRMY 20.62
- 52 Week Low
- GBX $37.77
- HRMY $26.47
- 52 Week High
- GBX $71.06
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- GBX 48.25
- HRMY 69.53
- Support Level
- GBX $42.49
- HRMY $29.82
- Resistance Level
- GBX $45.27
- HRMY $30.61
- Average True Range (ATR)
- GBX 1.21
- HRMY 1.12
- MACD
- GBX 0.69
- HRMY 0.74
- Stochastic Oscillator
- GBX 77.25
- HRMY 92.78
About GBX Greenbrier Companies Inc. (The)
Greenbrier Companies Inc designs, manufactures, and markets railroad freight car equipment in North America and Europe, marine barges in North America and provides wheel services, railcar refurbishment, and parts, leasing and other services to the railroad. Its segments include Manufacturing, Maintenance Services and Leasing & Management Services. The company generates a majority of its revenue from the manufacturing segment. Geographically, it derives a majority of revenue from the United States.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.